News
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
15h
Zacks.com on MSNNovavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Brad Smith outlines the top stories on Wall Street as part of Yahoo Finance's Market Minute. Vertiv Holdings (VRT) stock is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results